# Neurogene Inc. (NGNE) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Neurogene Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/NGNE/mda/fy2025/): filed 2026-03-24; accession 0001404644-26-000019 (https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/ngne-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/NGNE/mda/fy2024/): filed 2025-03-24; accession 0001404644-25-000012 (https://www.sec.gov/Archives/edgar/data/1404644/000140464425000012/ngne-20241231.htm)
- [FY 2023 MD&A](/company/NGNE/mda/fy2023/): filed 2024-03-18; accession 0001404644-24-000020 (https://www.sec.gov/Archives/edgar/data/1404644/000140464424000020/ngne-20231231.htm)
- [FY 2022 MD&A](/company/NGNE/mda/fy2022/): filed 2023-03-20; accession 0001628280-23-008602 (https://www.sec.gov/Archives/edgar/data/1404644/000162828023008602/nltx-20221231.htm)
- [FY 2021 MD&A](/company/NGNE/mda/fy2021/): filed 2022-03-01; accession 0001628280-22-004491 (https://www.sec.gov/Archives/edgar/data/1404644/000162828022004491/nltx-20211231.htm)

Back to /company/NGNE/